» Articles » PMID: 32994333

SARS-CoV-2 Seroprevalence Among a Southern U.S. Population Indicates Limited Asymptomatic Spread Under Physical Distancing Measures

Abstract

Characterizing the asymptomatic spread of SARS-CoV-2 is important for understanding the COVID-19 pandemic. This study was aimed at determining asymptomatic spread of SARS-CoV-2 in a suburban, Southern U.S. population during a period of state restrictions and physical distancing mandates. This is one of the first published seroprevalence studies from North Carolina and included multicenter, primary care, and emergency care facilities serving a low-density, suburban and rural population since description of the North Carolina state index case introducing the SARS-CoV-2 respiratory pathogen to this population. To estimate point seroprevalence of SARS-CoV-2 among asymptomatic individuals over time, two cohort studies were examined. The first cohort study, named ScreenNC, was comprised of outpatient clinics, and the second cohort study, named ScreenNC2, was comprised of inpatients unrelated to COVID-19. Asymptomatic infection by SARS-CoV-2 (with no clinical symptoms) was examined using an Emergency Use Authorization (EUA)-approved antibody test (Abbott) for the presence of SARS-CoV-2 IgG. This assay as performed under CLIA had a reported specificity/sensitivity of 100%/99.6%. ScreenNC identified 24 out of 2,973 (0.8%) positive individuals among asymptomatic participants accessing health care during 28 April to 19 June 2020, which was increasing over time. A separate cohort, ScreenNC2, sampled from 3 March to 4 June 2020, identified 10 out of 1,449 (0.7%) positive participants. This study suggests limited but accelerating asymptomatic spread of SARS-CoV-2. Asymptomatic infections, like symptomatic infections, disproportionately affected vulnerable communities in this population, and seroprevalence was higher in African American participants than in White participants. The low, overall prevalence may reflect the success of shelter-in-place mandates at the time this study was performed and of maintaining effective physical distancing practices among suburban populations. Under these public health measures and aggressive case finding, outbreak clusters did not spread into the general population.

Citing Articles

Polymerase chain reaction-positivity and predictors for SARS-CoV-2 infection among diagnosed cases' in North West Ethiopia.

Kebede F, Kebede T Health Sci Rep. 2023; 6(10):e1663.

PMID: 37900095 PMC: 10603290. DOI: 10.1002/hsr2.1663.


Estimation of SARS-CoV-2 Seroprevalence in Central North Carolina: Accounting for Outcome Misclassification in Complex Sample Designs.

Vias N, Cassidy C, Edwards J, Xiong K, Beatty Parker C, Aiello A Epidemiology. 2023; 34(5):721-731.

PMID: 37527450 PMC: 10403265. DOI: 10.1097/EDE.0000000000001625.


Prediction of Needle Physiological Traits Using UAV Imagery for Breeding Selection of Slash Pine.

Niu X, Song Z, Xu C, Wu H, Luan Q, Jiang J Plant Phenomics. 2023; 5:0028.

PMID: 36939412 PMC: 10017333. DOI: 10.34133/plantphenomics.0028.


Intra-Host Evolution Provides for the Continuous Emergence of SARS-CoV-2 Variants.

Landis J, Moorad R, Pluta L, Caro-Vegas C, McNamara R, Eason A mBio. 2023; 14(2):e0344822.

PMID: 36786605 PMC: 10127995. DOI: 10.1128/mbio.03448-22.


Scaling Biosafety Up During and Down After the COVID-19 Pandemic.

Dittmer D, Eason A, Juarez A Appl Biosaf. 2023; 27(4):247-254.

PMID: 36761994 PMC: 9902049. DOI: 10.1089/apb.2022.0008.


References
1.
Theel E, Harring J, Hilgart H, Granger D . Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. J Clin Microbiol. 2020; 58(8). PMC: 7383546. DOI: 10.1128/JCM.01243-20. View

2.
Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E . Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. JAMA. 2020; 323(23):2425-2427. PMC: 7235907. DOI: 10.1001/jama.2020.8279. View

3.
Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26(6):845-848. DOI: 10.1038/s41591-020-0897-1. View

4.
Ng D, Goldgof G, Shy B, Levine A, Balcerek J, Bapat S . SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nat Commun. 2020; 11(1):4698. PMC: 7499171. DOI: 10.1038/s41467-020-18468-8. View

5.
Kim S, Jeong H, Yu Y, Shin S, Kim S, Oh T . Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. Int J Infect Dis. 2020; 95:441-443. PMC: 7196533. DOI: 10.1016/j.ijid.2020.04.083. View